IFP Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

IFP Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-438	Closed	-$2.34K	–	3366
2024 Q1	$2.34K	Hold	438	–	–	﹤0.01%	2647
2023 Q4	$3.41K	Hold	438	–	–	﹤0.01%	2535
2023 Q3	$1.73K	Hold	438	–	–	﹤0.01%	2875
2023 Q2	$1.38K	Hold	438	–	–	﹤0.01%	2996
2023 Q1	$2.66K	Sell	438 -355	-45%	-$1.38K	﹤0.01%	2802
2022 Q4	$6K	Buy	793 +743	+1,486%	+$3.22K	﹤0.01%	3740
2022 Q3	$1K	Buy	50 +45	+900%	+$366	﹤0.01%	4724
2022 Q2	$1K	Hold	5	–	–	﹤0.01%	4492
2022 Q1	$1K	Hold	5	–	–	﹤0.01%	4490
2021 Q4	$1K	Hold	5	–	–	﹤0.01%	3157
2021 Q3	$1K	Buy	+5	New	+$244	﹤0.01%	3171
2021 Q2	–	Sell	-2	Closed	-$118	–	3274
2021 Q1	$0	Sell	2 -9	-82%	-$935	﹤0.01%	3261
2020 Q4	$1K	Buy	+11	New	+$1K	﹤0.01%	2841
2017 Q4	–	Sell	-50	Closed	-$7K	–	4144
2017 Q3	$7K	Buy	+50	New	+$9.4K	﹤0.01%	3248

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

IFP Advisors's SYRS Position: Q2 2024 in Review

IFP Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2024, closing a stake of 438 shares — an estimated $2.34K sold.

IFP Advisors first reported a position in SYRS in Q3 2017 and held it in 14 quarters. The position peaked at $7K in Q3 2017. 70 funds tracked by Wall St. Rank hold SYRS as of Q2 2024.

IFP Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
IFP Advisors sold 438 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $2.34K.
IFP Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 14 quarters.
IFP Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $7K in Q3 2017.
70 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2024.

Based on IFP Advisors's 13F filing for Q2 2024, filed 30 Jul 2024.